PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
January 23, 2026Journal of Crohn s and Colitis

P0870Dynamic profiling of circulating micro-RNAs reveals early signatures of infliximab response in ulcerative colitis

View Full Paper
Ask AI
Bookmark
Share

Authors

TITommaso InnocentiAPAdriano PasquiFSF Scolari

Discussion

Loading...

Member takes

Overview

Prospective analysis reveals miRNA signatures predicting infliximab response in ulcerative colitis, suggesting early biomarkers for treatment.

Key Points

  • To identify circulating micro-RNAs associated with treatment response in ulcerative colitis patients receiving infliximab.
  • Conducted a prospective study with patients starting intravenous infliximab.
  • Classified patients as responders or non-responders after 12 months.
  • Collected plasma samples at baseline and post-induction.
  • Analyzed circulating miRNAs using Nanostring Human v3 miRNA Assay.
  • Performed differential expression analysis and ROC analyses.
  • Identified distinct miRNA expression patterns between responders and non-responders.
  • Upregulated miRNAs in responders were linked to T-cell differentiation and complement activation.
  • miR-200a-3p was the most accurate predictor of remission with AUC=0.933 after induction.
  • Findings indicate that specific miRNA signatures may serve as early biomarkers for treatment response.

Cite This Study

Innocenti et al. (2026) studied this question.

synapsesocial.com/papers/697310b0c8125b09b0d20697https://doi.org/10.1093/ecco-jcc/jjaf231.1051
View Full Paper
Ask AI
Bookmark
Share